Oncology

A test that uses next-generation sequencing (NGS) has been approved to detect and monitor minimal residual disease in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL).

Here are the top 5 articles for the month of September.

Loyola University Chicago and Loyola Medicine announced plans this week to develop their own chimeric antigen receptor T-cells that would have less toxic side effects.

Earlier this week, 3 studies were released that investigated the financial difficulties seen in patients living with cancer. Such difficulties are referred to as “financial toxicity,” which was studied in patients with metastatic breast cancer and older patients, as well as the conversations about cost of care that women with breast cancer have with their physicians.

Earlier this week, drug manufacturer Astrazeneca announced the results from a phase 3 trial studying durvalumab (Imfinzi) among patients with stage III unresectable non­–small cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy.

With cancer costs rising and patients with cancer disproportionately facing financial toxicity, alternative payment and care delivery models are thought to help alleviate some of the cost burden. However, a review finds limited evidence available to evaluate the efficacy of alternative payment and care models in cancer care.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

The flagship event of more than 450 Biden Cancer Community Summits convening throughout the day is focusing on sharing experiences, promoting new solutions, and bridging gaps in cancer care.

Although many different treatments exist for basal cell carcinoma (BCC), many methods have not been compared in head-to-head randomized trials. A review recently published in Annals of Internal Medicine looked to evaluate the comparative effectiveness and safety of treatments in adults with BCC.

This week, the top managed care news included the Senate overwhelmingly voting to ban pharmacist gag clauses; a study found the current vaccine pipeline for HIV, tuberculosis, and malaria may fall short; an expert noted a trend of healthcare cost data seeping into nonhealthcare companies’ earnings calls.

Amgen’s pipeline drug AMG 420, a bispecific T-cell engager (BiTE) for the treatment of patients with relapsing/refractory multiple myeloma (RRMM), has found positive preliminary results in a phase 1 trial.